Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
34
PDSB Quote, Financials, Valuation and Earnings
Last price:
$0.86
Seasonality move
:
-8.46%
Day range:
$0.83 - $0.91
52-week range:
$0.70 - $2.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.04x
Volume:
379.7K
Avg. volume:
1M
1-year change:
-56.5%
Market cap:
$47.6M
Revenue:
--
EPS (TTM):
-$0.82
Analysts' Opinion
-
Consensus RatingPDS Biotechnology Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.50, PDS Biotechnology Corp. has an estimated upside of 762.07% from its current price of $0.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.87.
Fair Value
-
According to the consensus of 3 analysts, PDS Biotechnology Corp. has 762.07% upside to fair value with a price target of $7.50 per share.
PDSB vs. S&P 500
-
Over the past 5 trading days, PDS Biotechnology Corp. has overperformed the S&P 500 by 12.49% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PDS Biotechnology Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PDS Biotechnology Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter PDS Biotechnology Corp. reported revenues of --.
Earnings Growth
-
PDS Biotechnology Corp. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter PDS Biotechnology Corp. reported earnings per share of -$0.19.
Enterprise value:
39.4M
EV / Invested capital:
1.44x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$60.5K
Return On Assets:
-79.28%
Net Income Margin (TTM):
--
Return On Equity:
-196.47%
Return On Invested Capital:
-91.45%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$175K | -$59.1K | -$60.5K | -$15.1K | -$15.1K | |
| Operating Income | -$51.5M | -$39.4M | -$32.2M | -$10.2M | -$8.1M | |
| EBITDA | -$51.3M | -$39.3M | -$32.2M | -$10.2M | -$8.1M | |
| Diluted EPS | -$1.71 | -$1.17 | -$0.82 | -$0.29 | -$0.19 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $71.3M | $74.4M | $56.8M | $52.1M | $27.9M | |
| Total Assets | $71.7M | $74.9M | $57.2M | $52.5M | $34.7M | |
| Current Liabilities | $3.6M | $4.8M | $9.2M | $18.3M | $13.3M | |
| Total Liabilities | $3.9M | $27.8M | $32.7M | $30.4M | $25.3M | |
| Total Equity | $67.9M | $47.1M | $24.5M | $22M | $9.5M | |
| Total Debt | $521.7K | $23M | $23.6M | $24.7M | $18M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.7M | -$35.3M | -$32.3M | -$8M | -$5.9M | |
| Cash From Investing | -- | -$29K | -- | -- | -- | |
| Cash From Financing | $15.3M | $30.8M | $8.7M | $17.2K | $241.2K | |
| Free Cash Flow | -$32.7M | -$35.3M | -$32.3M | -$8M | -$5.9M | |
PDSB
Sector
Market Cap
$47.6M
$28.5M
Price % of 52-Week High
38.13%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-31.56%
-1.33%
1-Year Price Total Return
-56.5%
-20.32%
Beta (5-Year)
1.107
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.80
200-day SMA
Sell
Level
$1.19
Bollinger Bands (100)
Sell
Level
0.89 - 1.19
Chaikin Money Flow
Sell
Level
-10.7M
20-day SMA
Buy
Level
$0.83
Relative Strength Index (RSI14)
Buy
Level
51.87
ADX Line
Buy
Level
15.59
Williams %R
Neutral
Level
-28.3262
50-day SMA
Sell
Level
$0.91
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
4.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.1137)
Sell
CA Score
(Annual)
Level (-3.9095)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.0007)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
Stock Forecast FAQ
In the current month, PDSB has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PDSB average analyst price target in the past 3 months is $7.50.
-
Where Will PDS Biotechnology Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that PDS Biotechnology Corp. share price will rise to $7.50 per share over the next 12 months.
-
What Do Analysts Say About PDS Biotechnology Corp.?
Analysts are divided on their view about PDS Biotechnology Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PDS Biotechnology Corp. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is PDS Biotechnology Corp.'s Price Target?
The price target for PDS Biotechnology Corp. over the next 1-year time period is forecast to be $7.50 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PDSB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PDS Biotechnology Corp. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PDSB?
You can purchase shares of PDS Biotechnology Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PDS Biotechnology Corp. shares.
-
What Is The PDS Biotechnology Corp. Share Price Today?
PDS Biotechnology Corp. was last trading at $0.86 per share. This represents the most recent stock quote for PDS Biotechnology Corp.. Yesterday, PDS Biotechnology Corp. closed at $0.87 per share.
-
How To Buy PDS Biotechnology Corp. Stock Online?
In order to purchase PDS Biotechnology Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PDSB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PDSB
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
5.04x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
PDSB
Sector
Revenue growth
--
4.85%
Earnings growth
34.04%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.20
-$0.20
Profitability
PDSB
Sector
Profitability FY 2024
-$59.8K
$3.6M
Return on invested capital
-91.45%
-30.98%
Return on assets
-79.28%
-27.62%
Return on equity
-196.47%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
PDSB
Sector
Total cash
$26.2M
$27.2M
Short term investments
--
$25.7M
Total assets
$45.4M
$79.7M
Long term debt
$18M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
